Sensitivity analysis-guided model reduction of a mathematical model of pembrolizumab therapy for de novo metastatic MSI-H/dMMR colorectal cancer
Georgio Hawi, Peter S. Kim, Peter P. Lee

TL;DR
This paper presents a sensitivity analysis-guided reduction of a detailed mathematical model of pembrolizumab therapy in metastatic MSI-H/dMMR colorectal cancer, resulting in simplified yet accurate models for future research.
Contribution
The authors developed two simplified models of the immune response in MSI-H/dMMR colorectal cancer using sensitivity analysis, enhancing model tractability and extensibility.
Findings
Two models accurately replicate original dynamics
Simplified models facilitate future theoretical studies
Models preserve mechanistic interpretability
Abstract
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide and the leading cause of cancer-related deaths in adults under 55, involving a complex interplay of biological processes such as dendritic cell (DC) maturation and migration, T cell activation and proliferation, cytokine production, and T cell and natural killer (NK) cell-mediated cancer cell killing. Microsatellite instability-high (MSI-H) CRC and deficient mismatch repair (dMMR) CRC constitute 15% of all CRC and 4% of metastatic CRC, and exhibit remarkable responsiveness to immunotherapy, especially with PD-1 inhibitors such as pembrolizumab. Mathematical models of the underlying immunobiology and the interactions underpinning immune checkpoint blockade offer mechanistic insights into tumour--immune dynamics and provide avenues for treatment optimisation and the identification of novel therapeutic targets.…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsColorectal Cancer Treatments and Studies · Cancer Immunotherapy and Biomarkers · Veterinary medicine and infectious diseases
